Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US10555939B2 · kind B2 · utility
0Cited by
58References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 10, 2018 |
| Grant date | Feb 11, 2020 |
| Priority date | — |
| Expiry date | May 10, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.